Alexandra L Terrill1, Narineh Hartoonian1, Meghan Beier1, Rana Salem1, Kevin Alschuler1. 1. Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA, USA (ALT, NH, MB, RS, KA); and Veterans Affairs Puget Sound Health Care System, Multiple Sclerosis Center of Excellence West, Seattle, WA, USA (NH).
Abstract
BACKGROUND: Generalized anxiety disorder (GAD) is common in multiple sclerosis (MS) but understudied. Reliable and valid measures are needed to advance clinical care and expand research in this area. The objectives of this study were to examine the psychometric properties of the 7-item Generalized Anxiety Disorder Scale (GAD-7) in individuals with MS and to analyze correlates of GAD. METHODS: Participants (N = 513) completed the anxiety module of the Patient Health Questionnaire (GAD-7). To evaluate psychometric properties of the GAD-7, the sample was randomly split to conduct exploratory and confirmatory factor analyses. RESULTS: Based on the exploratory factor analysis, a one-factor structure was specified for the confirmatory factor analysis, which showed excellent global fit to the data (χ(2) 12 = 15.17, P = .23, comparative fit index = 0.99, root mean square error of approximation = 0.03, standardized root mean square residual = 0.03). The Cronbach alpha (0.75) indicated acceptable internal consistency for the scale. Furthermore, the GAD-7 was highly correlated with the Hospital Anxiety and Depression Scale-Anxiety (r = 0.70). Age and duration of MS were both negatively associated with GAD. Higher GAD-7 scores were observed in women and individuals with secondary progressive MS. Individuals with higher GAD-7 scores also endorsed more depressive symptoms. CONCLUSIONS: These findings support the reliability and internal validity of the GAD-7 for use in MS. Correlational analyses revealed important relationships with demographics, disease course, and depressive symptoms, which suggest the need for further anxiety research.
BACKGROUND: Generalized anxiety disorder (GAD) is common in multiple sclerosis (MS) but understudied. Reliable and valid measures are needed to advance clinical care and expand research in this area. The objectives of this study were to examine the psychometric properties of the 7-item Generalized Anxiety Disorder Scale (GAD-7) in individuals with MS and to analyze correlates of GAD. METHODS:Participants (N = 513) completed the anxiety module of the Patient Health Questionnaire (GAD-7). To evaluate psychometric properties of the GAD-7, the sample was randomly split to conduct exploratory and confirmatory factor analyses. RESULTS: Based on the exploratory factor analysis, a one-factor structure was specified for the confirmatory factor analysis, which showed excellent global fit to the data (χ(2) 12 = 15.17, P = .23, comparative fit index = 0.99, root mean square error of approximation = 0.03, standardized root mean square residual = 0.03). The Cronbach alpha (0.75) indicated acceptable internal consistency for the scale. Furthermore, the GAD-7 was highly correlated with the Hospital Anxiety and Depression Scale-Anxiety (r = 0.70). Age and duration of MS were both negatively associated with GAD. Higher GAD-7 scores were observed in women and individuals with secondary progressive MS. Individuals with higher GAD-7 scores also endorsed more depressive symptoms. CONCLUSIONS: These findings support the reliability and internal validity of the GAD-7 for use in MS. Correlational analyses revealed important relationships with demographics, disease course, and depressive symptoms, which suggest the need for further anxiety research.
Authors: Bernd Löwe; Oliver Decker; Stefanie Müller; Elmar Brähler; Dieter Schellberg; Wolfgang Herzog; Philipp Yorck Herzberg Journal: Med Care Date: 2008-03 Impact factor: 2.983
Authors: Hannu Koponen; Christer Allgulander; Janelle Erickson; Eduardo Dunayevich; Yili Pritchett; Michael J Detke; Susan G Ball; James M Russell Journal: Prim Care Companion J Clin Psychiatry Date: 2007
Authors: Kerina H Jones; David V Ford; Philip A Jones; Ann John; Rodden M Middleton; Hazel Lockhart-Jones; Lisa A Osborne; J Gareth Noble Journal: PLoS One Date: 2012-07-30 Impact factor: 3.240
Authors: Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde Journal: Curr Neurol Neurosci Rep Date: 2016-12 Impact factor: 5.081
Authors: Anna M Baker; Janet T Holbrook; Abebaw M Yohannes; Michelle N Eakin; Elizabeth A Sugar; Robert J Henderson; Anne S Casper; David A Kaminsky; Alexis L Rea; Anne M Mathews; Loretta G Que; Joe W Ramsdell; Lynn B Gerald; Robert A Wise; Nicola A Hanania Journal: Ann Am Thorac Soc Date: 2018-08
Authors: Brittany Litster; Kirsten M Fiest; Scott B Patten; John D Fisk; John R Walker; Lesley A Graff; James M Bolton; Jitender Sareen; James J Marriott; Lindsay I Berrigan; Charles N Bernstein; Ryan Zarychanski; Alexander Singer; Carol A Hitchon; Christine A Peschken; Ruth Ann Marrie Journal: Int J MS Care Date: 2016 Nov-Dec
Authors: Daniela A Pimentel Maldonado; Justin R Eusebio; Lilyana Amezcua; Eleni S Vasileiou; Ellen M Mowry; Christopher C Hemond; Raffaella Umeton Pizzolato; Idanis Berrios Morales; Irina Radu; Carolina Ionete; Kathryn C Fitzgerald Journal: Mult Scler Relat Disord Date: 2021-12-05 Impact factor: 4.808
Authors: Johanna T W Snijkers; Wendy van den Oever; Zsa Zsa R M Weerts; Lisa Vork; Zlatan Mujagic; Carsten Leue; Martine A M Hesselink; Joanna W Kruimel; Jean W M Muris; Roel M M Bogie; Ad A M Masclee; Daisy M A E Jonkers; Daniel Keszthelyi Journal: Neurogastroenterol Motil Date: 2021-05-03 Impact factor: 3.960